Intel's Weak Revenue Guidance Validates DeepValue's Turnaround Concerns, Keeping Stock in 'WAIT' Zone

What happened

Intel's stock dropped over 6% in February as investors digested weak revenue guidance for the current quarter, which missed analysts' consensus expectations. This aligns with the DeepValue report's core thesis that Intel's high-stakes turnaround depends on easing severe supply constraints, particularly from its 18A manufacturing ramp, starting in Q2 2026 after a depleted-buffer Q1. The report underscores Intel Foundry's massive $10.3 billion operating loss in 2025, driven almost entirely by internal demand with only $307 million in external revenue, highlighting the structural drag on profitability. Management's weak guidance suggests persistent manufacturing bottlenecks or softer demand, contradicting optimistic narratives and increasing execution risk ahead of the critical Q2-Q3 2026 window. Thus, the market's skepticism is reinforced, as Intel must now prove it can convert demand into shipments and curb foundry losses to avoid slipping toward the bear scenario.

Implication

The weak guidance confirms that Intel's supply constraints are not easing as anticipated, raising the probability of the bear scenario where foundry losses persist near $10 billion and buffer inventory stays depleted. This heightens the urgency for Q2-Q3 2026 results to demonstrate tangible yield improvements and shipment unlocks, as failure here could trigger impairments on the $105 billion net PP&E base. Investors must monitor upcoming quarters for evidence that 18A throughput is breaking bottlenecks and that external foundry commitments emerge to justify future node investments. Without clear progress by mid-2026, the stock risks re-rating toward the $32 bear case implied value, reflecting heightened downside from capital misallocation and incentive clawbacks. Therefore, maintain a 'WAIT' stance, as the current price offers no margin of safety amid negative EPS and high leverage.

Thesis delta

The weak revenue guidance does not shift the fundamental thesis but reinforces the existing bearish risks, moving the needle slightly toward the scenario where supply constraints persist and foundry losses fail to narrow. It underscores that Intel's guided Q2 improvement is not assured, increasing the stakes for upcoming quarterly reports to validate the manufacturing turnaround. However, the thesis remains unchanged—a 'WAIT' rating persists until observable proof emerges in H1 2026.